Key Points
- CEO Kevin Tang bought 206,005 Aurinia Pharmaceuticals shares on June 2 at an average price of $15.28, totaling about $3.15 million. After the purchase, he owned 13.04 million shares, valued at roughly $199.3 million.
- Tang has been actively buying recently, including purchases of 343,620 shares on June 1 and 264,981 shares on May 29, both at around $15.3 per share.
- Aurinia posted solid quarterly results, with EPS of $0.25 beating estimates and revenue of $77.71 million slightly topping forecasts. The stock was trading near $15.39, and analysts currently rate it a consensus Hold with a $17.25 target price.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) CEO Kevin Tang purchased 206,005 shares of the stock in a transaction on Tuesday, June 2nd. The stock was acquired at an average cost of $15.28 per share, for a total transaction of $3,147,756.40. Following the acquisition, the chief executive officer directly owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kevin Tang also recently made the following trade(s):
- On Monday, June 1st, Kevin Tang purchased 343,620 shares of Aurinia Pharmaceuticals stock. The stock was acquired at an average cost of $15.28 per share, for a total transaction of $5,250,513.60.
- On Friday, May 29th, Kevin Tang purchased 264,981 shares of Aurinia Pharmaceuticals stock. The stock was acquired at an average cost of $15.31 per share, for a total transaction of $4,056,859.11.
Aurinia Pharmaceuticals Trading Up 0.5%
Shares of Aurinia Pharmaceuticals stock opened at $15.39 on Wednesday. The firm has a market capitalization of $1.98 billion, a PE ratio of 7.09 and a beta of 1.41. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. The company's fifty day moving average price is $15.51 and its two-hundred day moving average price is $15.25. Aurinia Pharmaceuticals Inc has a 52-week low of $7.28 and a 52-week high of $16.88.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.07. The firm had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. On average, analysts expect that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current year.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Several large investors have recently made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership grew its holdings in shares of Aurinia Pharmaceuticals by 213.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company's stock worth $37,283,000 after purchasing an additional 2,297,903 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Aurinia Pharmaceuticals by 1,272.5% in the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company's stock worth $16,389,000 after purchasing an additional 1,375,072 shares during the last quarter. Kotler Kevin bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $19,536,000. Two Sigma Investments LP grew its holdings in shares of Aurinia Pharmaceuticals by 728.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company's stock worth $14,819,000 after purchasing an additional 1,179,219 shares during the last quarter. Finally, Man Group plc grew its holdings in shares of Aurinia Pharmaceuticals by 368.9% in the 4th quarter. Man Group plc now owns 852,671 shares of the biotechnology company's stock worth $13,600,000 after purchasing an additional 670,812 shares during the last quarter. Institutional investors own 36.83% of the company's stock.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered shares of Aurinia Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $17.25.
View Our Latest Analysis on AUPH
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
